| Study |
Reference |
|
Battino (Epilepsy), 2024
|
Battino Risk of Major Congenital Malformations and Exposure to Antiseizure Medication Monotherapy. JAMA Neurol 2024; 81:481-489 Tomson Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurol 2018; 17:530-538 Tomson T Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol 2011;10:609-17
|
|
Bjørk (Controls exposed to Lamotrigine, sick) (Mixed indications), 2022
|
Bjørk Association of Prenatal Exposure to Antiseizure Medication With Risk of Autism and Intellectual Disability. JAMA Neurol 2022; :
|
|
Bjørk (Controls unexposed NOS) (Mixed indications), 2022
|
Bjørk Association of Prenatal Exposure to Antiseizure Medication With Risk of Autism and Intellectual Disability. JAMA Neurol 2022; :
|
|
Bjørk (Controls unexposed, sick) (Mixed indications), 2022
|
Bjørk Association of Prenatal Exposure to Antiseizure Medication With Risk of Autism and Intellectual Disability. JAMA Neurol 2022; :
|
|
Blotière (Controls exposed to Lamotrigine, sick) (Other indications), 2019
|
Blotière Risks of 23 specific malformations associated with prenatal exposure to 10 antiepileptic drugs. Neurology 2019; 93:e167-e180
|
|
Blotière (Controls unexposed NOS) (Other indications), 2019
|
Blotière Risks of 23 specific malformations associated with prenatal exposure to 10 antiepileptic drugs. Neurology 2019; 93:e167-e180
|
|
Christensen (All indications) (Controls exposed to LTG), 2024
|
Christensen Prenatal exposure to antiseizure medications and fetal growth: a population-based cohort study from the Nordic countries. Lancet Reg Health Eur 2024; 38:100849
|
|
Christensen (All indications) (Controls unexposed, general population), 2024
|
Christensen Prenatal exposure to antiseizure medications and fetal growth: a population-based cohort study from the Nordic countries. Lancet Reg Health Eur 2024; 38:100849
|
|
Coste (Controls exposed to Lamotrigine, sick) (Mixed indications), 2020
|
Blotière Risk of early neurodevelopmental outcomes associated with prenatal exposure to the antiepileptic drugs most commonly used during pregnancy: a French nationwide population-based cohort study. BMJ Open 2020; 10:e034829 Coste Risk of early neurodevelopmental disorders associated with in utero exposure to valproate and other antiepileptic drugs: a nationwide cohort study in France. Sci Rep 2020; 10:17362
|
|
Coste (Controls unexposed, NOS) (Mixed indications), 2020
|
Coste Risk of early neurodevelopmental disorders associated with in utero exposure to valproate and other antiepileptic drugs: a nationwide cohort study in France. Sci Rep 2020; 10:17362
|
|
Dreier (Controls exposed to LTG), 2023
|
Dreier Prenatal Exposure to Antiseizure Medication and Incidence of Childhood- and Adolescence-Onset Psychiatric Disorders. JAMA Neurol 2023; 80:568-577
|
|
Dreier (Controls unexposed, sick), 2023
|
Dreier Prenatal Exposure to Antiseizure Medication and Incidence of Childhood- and Adolescence-Onset Psychiatric Disorders. JAMA Neurol 2023; 80:568-577
|
|
Dudukina (Controls exposed to LTG) (Mixed indications), 2023
|
Dudukina Prenatal exposure to pregabalin, birth outcomes and neurodevelopment - a population-based cohort study in four Nordic countries. Drug Saf 2023; 46:661-675 Toft A Population-based Cohort Study of Pregabalin to Characterize Pregnancy Outcomes A0081359 Non-interventional final study report. 2020; 1-71
|
|
Dudukina (Controls unexposed, NOS) (Mixed indications), 2023
|
Dudukina Prenatal exposure to pregabalin, birth outcomes and neurodevelopment - a population-based cohort study in four Nordic countries. Drug Saf 2023; 46:661-675 Toft A Population-based Cohort Study of Pregabalin to Characterize Pregnancy Outcomes A0081359 Non-interventional final study report. 2020; 1-71
|
|
Källén (Controls exposed to Lamotrigine, sick) (Indications NOS), 2013
|
Källén B The use of central nervous system active drugs during pregnancy. Pharmaceuticals (Basel) 2013;6:1221-86
|
|
Källén (Controls unexposed, NOS) (Indications NOS), 2013
|
Källén B The use of central nervous system active drugs during pregnancy. Pharmaceuticals (Basel) 2013;6:1221-86
|
|
Kaskal (Indications NOS), 2024
|
Kaskal Evaluation of the teratogenic effects of pregabalin usage during pregnancy: A multicenter case-control study. North Clin Istanb 2024; 11:460-465
|
|
Kilic (Controls exposed to Lamotrigine, sick) (Mixed indications), 2014
|
Kilic D Birth outcomes after prenatal exposure to antiepileptic drugs--a population-based study. Epilepsia 2014;55:1714-21
|
|
Kilic (Controls unexposed NOS) (Mixed indications), 2014
|
Kilic D Birth outcomes after prenatal exposure to antiepileptic drugs--a population-based study. Epilepsia 2014;55:1714-21
|
|
Kilic (Controls unexposed, sick) (Mixed indications), 2014
|
Kilic D Birth outcomes after prenatal exposure to antiepileptic drugs--a population-based study. Epilepsia 2014;55:1714-21
|
|
Madley-Dowd_SE (Pregabalin) (Controls exposed to LTG) (Mixed indications), 2024
|
Madley-Dowd Antiseizure medication use during pregnancy and children's neurodevelopmental outcomes. Nat Commun 2024; 15:9640
|
|
Madley-Dowd_SE (Pregabalin) (Controls unexposed, general pop) (Mixed indications), 2024
|
Madley-Dowd Antiseizure medication use during pregnancy and children's neurodevelopmental outcomes. Nat Commun 2024; 15:9640
|
|
Madley-Dowd_SE (Pregabalin) (Controls unexposed, sibling) (Mixed indications), 2024
|
Madley-Dowd Antiseizure medication use during pregnancy and children's neurodevelopmental outcomes. Nat Commun 2024; 15:9640
|
|
Madley-Dowd_UK (Pregabalin) (Controls exposed to LTG) (Mixed indications), 2024
|
Madley-Dowd Antiseizure medication use during pregnancy and children's neurodevelopmental outcomes. Nat Commun 2024; 15:9640
|
|
Madley-Dowd_UK (Pregabalin) (Controls unexposed, general pop) (Mixed indications), 2024
|
Madley-Dowd Antiseizure medication use during pregnancy and children's neurodevelopmental outcomes. Nat Commun 2024; 15:9640
|
|
Madley-Dowd_UK (Pregabalin) (Controls unexposed, sibling) (Mixed indications), 2024
|
Madley-Dowd Antiseizure medication use during pregnancy and children's neurodevelopmental outcomes. Nat Commun 2024; 15:9640
|
|
Margulis (Pregabalin) (Indications other than epilepsy), 2019
|
Margulis Relation of in-utero exposure to antiepileptic drugs to pregnancy duration and size at birth. PLoS One 2019; 14:e0214180
|
|
Patorno_MAX and MaketScan (Other indications), 2017
|
Patorno Pregabalin use early in pregnancy and the risk of major congenital malformations. Neurology 2017; 88:2020-2025
|
|
Razaz (Epilepsy), 2024
|
Razaz Risk of Perinatal and Maternal Morbidity and Mortality Among Pregnant Women With Epilepsy. JAMA Neurol 2024; 81:985-995
|
|
The NAAED (Controls exposed to LTG) (Indications NOS), 2023
|
Hernández-Díaz Comparative safety of antiepileptic drugs during pregnancy. Neurology 2012;78:1692-9 Lewis B. Holmes, M.D. (Director) Risk of malformations for specific AED in monotherapy and the control groups (Latest Study Data - October 2023) https://www.aedpregnancyregistry.org/ (Consulted 05/2022) Lewis Holmes Risk of malformations for specific AED in monotherapy and the control groups. Latest Study Data - October 2023. https://www.aedpregnancyregistry.org/ (Consulted September 2024)
|
|
The NAAED (Controls unexposed, disease free) (Indications NOS), 2023
|
Hernández-Díaz Comparative safety of antiepileptic drugs during pregnancy. Neurology 2012;78:1692-9 Lewis B. Holmes, M.D. (Director) Risk of malformations for specific AED in monotherapy and the control groups (Annual Update for 2022) https://www.aedpregnancyregistry.org/ (Consulted 05/2022) Lewis Holmes Risk of malformations for specific AED in monotherapy and the control groups. Latest Study Data - October 2023. https://www.aedpregnancyregistry.org/ (Consulted September 2024) Wyszynski Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology 2005; 64:961-5
|
|
Vajda (Controls exposed to Lamotrigine, sick), 2019
|
Jazayeri Outcomes of pregnancies in women taking antiepileptic drugs for non-epilepsy indications. Seizure 2018; 56:111-114 Vajda Antiepileptic drugs and foetal malformation: analysis of 20 years of data in a pregnancy register. Seizure 2019; 65:6-11
|
|
Vajda (Controls unexposed, sick), 2019
|
Jazayeri Outcomes of pregnancies in women taking antiepileptic drugs for non-epilepsy indications. Seizure 2018; 56:111-114 Vajda Antiepileptic drugs and foetal malformation: analysis of 20 years of data in a pregnancy register. Seizure 2019; 65:6-11
|
|
Veiby (Controls exposed to Lamotrigine, sick) (Mixed indications), 2014
|
Veiby Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy. J. Neurol. 2014; 261:579-88
|
|
Veiby (Controls unexposed, disease free) (Mixed indications), 2014
|
Veiby Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy. J. Neurol. 2014; 261:579-88
|
|
Veiby (Controls unexposed, sick) (Mixed indications), 2014
|
Veiby Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy. J. Neurol. 2014; 261:579-88
|
|
Winterfeld (Other indications), 2016
|
Winterfeld Pregnancy outcome following maternal exposure to pregabalin may call for concern. Neurology 2016; 86:2251-7
|
